Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | MGAT2 | Q10469 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2524379 | 0.83 | NPC1 (0.48) | F10NPC1RAB9ARXFP1SMN1; SMN2 | |
| SCHEMBL2178470 | 0.83 | F10 (0.73) | F10POLBNPC1RAB9AKDM1A | |
| SCHEMBL7154056 | 0.81 | ALDH1A1 (0.66) | POLBNPC1RAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL7091303 | 0.80 | MAPT (0.66) | NPC1RAB9ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL7148309 | 0.78 | MAPT (0.68) | F10POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7153529 | 0.77 | NPC1 (0.69) | F10POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL26090259 | 0.77 | NPC1 (0.53) | F10NPC1RAB9ARXFP1SMN1; SMN2 | |
| SCHEMBL5837944 | 0.77 | POLB (0.53) | POLBNPC1RAB9AKDM1AMAOA | |
| SCHEMBL78438 | 0.77 | SMN1; SMN2 (0.67) | F10POLBNPC1RAB9AKDM1A | |
| SCHEMBL7088328 | 0.76 | MAPT (0.68) | F10NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-10-20 | — | — | US | disclosed |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-06-18 | — | — | US | disclosed |
| US-8822458-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-09-02 | — | — | US | disclosed |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-11-28 | — | — | US | disclosed |
| US-8530505-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-01-03 | — | — | US | disclosed |
| US-8129378-B2 | Rivaroxaban and derivatives, synthesis; atherosclerosis; arthritis; Alzheimer's disease or cancer | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-21 | — | — | US | disclosed |
| US-7767702-B2 | Combinations of oxazolidinones such as rivaroxaban with a platelet aggregation inhibitor such as a clopidogrel for the prophylaxis and/or treatment of thromboembolic disorders | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-03 | — | — | US | disclosed |
| US-20100160301-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | BAYER HEALTHCARE AG | 2010-06-24 | — | — | US | disclosed |
| US-7157456-B2 | Anticoagulates for treating cardiovascular disorders, such as myocardial infarct, angina pectoris, restenoses after angioplasty, bypass, stroke; treatment of atherosclerosis, arthritis, Alzheimer's disease or cancer | BAYER HEALTHCARE AG (DE) | 2007-01-02 | — | — | US | disclosed |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2006-11-16 | — | — | US | disclosed |
| US-20060173047-A1 | Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics | BAYER AKTIENGESELLSCHAFT (DE) | 2006-08-03 | — | — | US | disclosed |
| US-7034017-B2 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER AKTIENGESELLSCHAFT (DE) | 2006-04-25 | — | — | US | disclosed |
| EP-1366029-B1 | SUBSTITUTED 2-OXO-3-PHENYL-5-CARBONYLAMINOMETHYL-1,3-OXAZOLINS AND THE UTILIZATION THEREOF AS ANTICOAGULANT AND ANTITHROMBOTIC AGENTS | BAYER HEALTHCARE AG (DE) | 2005-09-28 | — | — | EP | disclosed |
| US-20050080081-A1 | Substituted oxazolidinones and their use in the field of blood coagulation | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-04-14 | — | — | US | disclosed |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1366029-A1 | SUBSTITUTED 2-OXO-3-PHENYL-5-CARBONYLAMINOMETHYL-1,3-OXAZOLINS AND THE UTILIZATION THEREOF AS ANTICOAGULANT AND ANTITHROMBOTIC AGENTS | Bayer Aktiengesellschaft (DE) | 2003-12-03 | — | — | EP | disclosed |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2003-08-14 | — | — | US | disclosed |
| WO-2002064575-A1 | SUBSTITUTED 2-OXO-3-PHENYL-5-CARBONYLAMINOMETHYL-1,3-OXAZOLINS AND THE UTILIZATION THEREOF AS ANTICOAGULANT AND ANTITHROMBOTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173047-A1 | Substituted 2-oxo-3-phenyl-5-carbonylaminomethyl-1, 3-oxazolines and their use as anticoagulant and antithrombotics | F2, SERPINC1, PROC | F10 27/4885POLB 3091/4885NPC1 2432/4885 |
| US-20160303138-A1 | Combination Therapy Of Substituted Oxazolidinones | P2RY12, P2RY11, P2RY1 | F10 1174/4885POLB 1805/4885NPC1 4495/4885 |
| US-20130005701-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885POLB 1473/4885NPC1 3746/4885 |
| US-20130316999-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885POLB 1473/4885NPC1 3746/4885 |
| US-20040242660-A1 | Combinations of oxazolidinones with other active ingredients for the prophylaxis and/or treatment of thromboembolic disorders | SERPINC1, XDH, SDHB | F10 41/4885POLB 687/4885NPC1 3833/4885 |
| US-20100267685-A1 | Methods For The Prophylaxis And/or Treatment Of Thromboembolic Disorders By Combination Therapy With Substituted Oxazolidinones | SERPINC1, SDHB, F2 | F10 34/4885POLB 697/4885NPC1 3693/4885 |
| US-20030153610-A1 | Substituted oxazolidinones and their in the field of blood coagulation | F2, F11, SERPINC1 | F10 9/4885POLB 1309/4885NPC1 2751/4885 |
| US-20100160301-A1 | MICROANGIOPATHY TREATMENT AND PREVENTION | SERPINC1, TFPI, F11 | F10 10/4885POLB 2938/4885NPC1 4038/4885 |
| US-20050080081-A1 | Substituted oxazolidinones and their use in the field of blood coagulation | F2, F11, F12 | F10 7/4885POLB 1758/4885NPC1 3165/4885 |
| US-20150166568-A1 | SUBSTITUTED OXAZOLIDINONES AND THEIR USE IN THE FIELD OF BLOOD COAGULATION | F2, F11, F13B | F10 9/4885POLB 1473/4885NPC1 3746/4885 |
| US-20060258724-A1 | Substituted Oxazolidinones and Their Use in the Field of Blood Coagulation | F2, F11, F13B | F10 9/4885POLB 1473/4885NPC1 3746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.